Skip to main content

Research Repository

Advanced Search

EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

Kurian, Kathreena M.; DeSouza, Ruth Mary; Haynes, Harry R.; Faulkner, Claire; Palmer, Abigail; Williams, Hannah; Wragg, Christopher; Haynes, Harry R; White, Paul; de Souza, Ruth-Mary; Williams, Maggie; Hopkins, Kirsten; Kurian, Kathreena M


Kathreena M. Kurian

Ruth Mary DeSouza

Harry R. Haynes

Claire Faulkner

Abigail Palmer

Hannah Williams

Christopher Wragg

Harry R Haynes

Paul White
Professor in Applied Statistics

Ruth-Mary de Souza

Maggie Williams

Kirsten Hopkins

Kathreena M Kurian


Copyright © 2014 The Neurosurgical Foundation. Introduction. EGFR and EGFRvIII analysis is of current interest because of new EGFRvIII vaccine trials opened in the UK. EGFR activation promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways. EGFRvIII is the most common variant resulting from an in-frame deletion of 801bp, leading to constitutively active EGFR. Method. 51 glioblastoma samples from a cohort of 50 patients were tested for EGFR amplification by FISH and immunohistochemistry and EGFRvIII expression by reverse-transcriptase PCR (RT-PCR), and immunohistochemistry. EGFR and EGFRvIII expression was compared with Overall Survival in the cohort. Results. Overall 22/51 samples (43%) were positive for EGFR, 16/51 (31%) were positive for EGFRvIII and 13/51 (25%) were positive for both. 9/51 cases (18%) were positive for EGFR alone, and 3/51 (6%) were positive for EGFRvIII alone. Of the EGFR positive cases, 22/51 (43%) were positive by FISH, 24/51 (47%) were positive by IHC and 2/51 (4%) were discrepant between methods (positive by IHC but non-amplified by FISH). Of the EGFRvIII positive cases, 16/51 (31%) were positive by RT-PCR, 17/51 (33%) were positive by IHC and 1/51 (2%) sample was discrepant (positive by IHC but not by RT-PCR). Neither EGFRvIII or EGFR are predictive of overall survival in this cohort. Conclusion. In our cohort, 25/51 (49%) of GBM showed EGFR alterations, including 16/51 (31%) with EGFRvIII. There was high concordance between IHC and FISH (96%) and IHC and RT-PCR (98%) as diagnostic methods. Neither EGFR or EGFRvIII is predictive of overall survival in this cohort. These results are key for selecting patients for novel individualised anti-EGFR therapies.


Kurian, K. M., DeSouza, R. M., Haynes, H. R., Faulkner, C., Palmer, A., Williams, H., …Kurian, K. M. (2015). EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. British Journal of Neurosurgery, 29(1), 23-29.

Journal Article Type Article
Publication Date Jan 1, 2015
Journal British Journal of Neurosurgery
Print ISSN 0268-8697
Electronic ISSN 1360-046X
Publisher Taylor & Francis
Peer Reviewed Peer Reviewed
Volume 29
Issue 1
Pages 23-29
Keywords epidermal growth factor receptor, glioma, glioblastoma
Public URL
Publisher URL